Abstract:Without question, natural products have provided the lion share of leads, if not drugs themselves, for the treatment of bacterial infections. The bacterial arms race, fueled by selection and survival pressures has delivered a natural arsenal of small molecules targeting the most essential of life processes. Antibiotics that target these critical intracellular processes face the formidable defense of both penetrating a bacterial cell membrane and avoiding efflux to exert their effect. These challenges are especially effective in Gram-negative (Gram-(-)) bacteria, which have a double membrane structure and efficient efflux systems from the combination of outer-membrane porins and inner membrane proton pumps. In this landscape of offense and defense, our clinically used antibiotics have only successfully targeted three intracellular processes for therapeutic intervention in Gram-(-) bacteria: dihydrofolate biosynthesis, transcription, and translation. Not surprisingly, such critical survival machinery is a popular target for bacterial warfare, and eight of our 14 classes of commonly used antibiotics target translation with the bacterial ribosome remaining one the most vetted targets for antimicrobial therapy. On the plus side, its anionic character attracts cationic inhibitors, which are generally more capable of penetrating the bacterial cell wall, and clinical resistance rates are usually manageable as mutation of such a highly evolved machine is difficult. On the down side, this highly evolved machine renders it difficult to inhibit selectively, and the inhibition of prokaryotic translation versus both eukaryotic cellular and mitochondrial translation is critical for clinical development and minimization of undesired toxicities.A class of natural products known as the "nucleoside antibiotics" have historically been recognized as universal inhibitors of the ribosome and can inhibit translation in prokaryotes, eukaryotes, and archaea. While they have served an essential role in dissecting the biochemical underpinnings of the enzymatic functions of the ribosome, they have not proven therapeutically useful as they target the highly conserved rRNA in the P-site and are toxic to mammalian cells. In this Account, we describe our studies on the natural product amicetin, a nucleoside antibiotic that we have demonstrated to break the rule of being a universal translation inhibitor. While the cytosine of amicetin mimics C75 of the 3'-CCA tail of the P-site tRNA akin to other nucleoside antibiotics, we advance a hypothesis that amicetin's unique interaction with the ribosomal protein uL16 exploits an untapped mechanism for selectively targeting the bacterial ribosome. A complex molecule comprised of a nucleoside, carbohydrates and amino acids, amicetin is also chemically unstable. Our initial attempts to stabilize and simplify this scaffold are presented with the ultimate goal of rebuilding the compound with improved penetrance to bacterial cells. If successful, this scaffold would demonstrate a path forward for a new class of antibiotics capable of selectively targeting the ribosomal P-site.

The Structural Basis for Inhibition of Ribosomal Translocation by Viomycin

Kinetically Competent Intermediates in the Translocation Step of Protein Synthesis

Single Molecule Structural Dynamics of Ribosome Before and During Translocation

Cryo-em Study of Trna Hybrid States Stabilized by Viomycin

Structural basis for contrasting activities of ribosome binding thiazole antibiotics.

The mechanism of error induction by the antibiotic viomycin provides insight into the fidelity mechanism of translation

Structural basis for differential inhibition of eukaryotic ribosomes by tigecycline

Rotational Motions of Domains in Elongation Factor G Detected by Single-Molecule Polarized Fluorescence Microscopy

Structural Basis of Mycobacterium Tuberculosis Transcription and Transcription Inhibition

[New Inhibitors Targeting Bacterial RNA Polymerase].

Medicinal chemistry of benzo[d]isoxazole-4,7-dione analogues identifies the ribosomal small subunit as a target for specific mycobacterial translational fidelity

Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3

Crystal Structures of EF-G–Ribosome Complexes Trapped in Intermediate States of Translocation

Structural basis for antibiotic resistance mediated by the Bacillus subtilis ABCF ATPase VmlR

Cryo-Em Structures of the 80s Ribosomes from Human Parasites Trichomonas Vaginalis and Toxoplasma Gondii

Distant Ribose 2'-O-Methylation of 23S rRNA Helix 69 Pre-Orders the Capreomycin Drug Binding Pocket at the Ribosome Subunit Interface

Alternative Mode of E-Site tRNA Binding in the Presence of a Downstream mRNA Stem Loop at the Entrance Channel

Dissecting the Nucleoside Antibiotics as Universal Translation Inhibitors

Structural and mechanistic basis for translation inhibition by macrolide and ketolide antibiotics

A Novel Actinobacteria-Specific Ribosome Hibernation Factor in Mycobacterium tuberculosis

Cryo-EM Structure of Mycobacterium Tuberculosis 50S Ribosomal Subunit Bound with Clarithromycin Reveals Dynamic and Specific Interactions with Macrolides